|Articles|October 1, 2018

Does being an orphan speed up FDA approval?

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Pharmaceutical Executive Daily: Policy Whiplash

ByNicholas Jacobus

October 13th 2025

Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil

ByNicholas Jacobus

October 13th 2025

Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors

ByNicholas Jacobus

October 13th 2025

Evolution of Biotech CFOs

ByNicholas Jacobus,Hunter Smith

October 13th 2025

Ypsomed Announces New U.S.-Based Manufacturing Site in North Carolina

ByNicholas Jacobus

October 10th 2025

Does being an orphan speed up FDA approval?

Newsletter

Related Content

Pharmaceutical Executive Daily: Policy Whiplash

Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil

Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors

Evolution of Biotech CFOs

Ypsomed Announces New U.S.-Based Manufacturing Site in North Carolina

Trending on PharmExec

How are the Drug Pricing Negotiations Impacting Pharma's Relationship with DC?

Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors

Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil

Policy Whiplash in Pharma: Navigating Volatility with Strategic Clarity

Evolution of Biotech CFOs